TPCW
EWTX icon

TD Private Client Wealth’s Edgewise Therapeutics EWTX Stock Holding History

TD Private Client Wealth’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60
Closed -$1.32K – 1447
2025
Q1 		$1.32K Buy
+60
New +$1.57K ﹤0.01% 1256

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TD Private Client Wealth's EWTX Position: Q2 2025 in Review

TD Private Client Wealth sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 60 shares — an estimated $1.32K sold.

TD Private Client Wealth first reported a position in EWTX in Q1 2025 and held it in 1 quarter. The position peaked at $1.32K in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • TD Private Client Wealth reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Private Client Wealth sold 60 Edgewise Therapeutics shares in Q2 2025, an estimated $1.32K.
  • TD Private Client Wealth first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Private Client Wealth's Edgewise Therapeutics position peaked at $1.32K in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on TD Private Client Wealth's 13F filing for Q2 2025, filed 15 Jul 2025.